In the latest edition of Managed Care, Precision for Value Payer Strategy Team members Ami Gopalan and Jeremy Schafer take a look at some of the cost-sharing strategies being employed by PBMs and ask the question, What latent effects might these programs have? (more…)
In the latest edition of Clinical Leader, Precision for Value’s Dominic Galante addresses how real-world evidence is being leveraged after the adoption of the 21st Century Cures Act, and provides some next steps for life science companies. (more…)
In a new article for Drug Discovery & Development, Precision Health Economics senior research economist Jason Shafrin addresses the use of real-world evidence, why we need it and how to effectively implement it. (more…)
Precision Health Economics Head of Medical, Dr. Ross Maclean, participates in a Q&A with patient advocate forum Conquer discussing the importance of personalized medicine. (more…)
In Managed Healthcare Executive, Precision Oncology’s Gerald Messerschmidt and Precision for Value’s Jeremy Schafer are tapped to provide their expert perspectives on the cost and value challenges facing the new class of CAR T-cell therapies. (more…)
Precision for Value is excited to be debuting a new publication– the Precision All Access Newsletter. All Access is an exclusive bi-monthly publication featuring key insights from our team of former payers intended specifically for market access leaders. (more…)
Pharmaceutical companies face many challenges: developing life-changing products that meet the needs of patients, physicians, and payers; adhering to regulatory standards; and managing health technology and payer scrutiny—all while trying to satisfy investors. (more…)
In a new commentary for US News & World Report, Precision Health Economics’ senior research economist Jason Shafrin defines and elaborates on the field of precision medicine. (more…)
In a new article on PM360, Precision for Value executive vice president Bruce Leavitt provides step-by-step guidance for drug makers who find their product on one of the recently released formulary exclusion lists. (more…)
In the latest edition of Managed Healthcare Executive, Jeremy Schafer, Precision for Value senior vice president, director of payer access solutions, discusses value in oncology and explains how payers are using value frameworks in their drug management process. (more…)
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
